Form 4: TG Therapeutics Director Yann Echelard Reports Acquisition of 22,250 Shares

Director Yann Echelard reports acquisition of 22,250 shares of TG Therapeutics common stock through a grant of restricted shares.

Summary

• On June 19, 2024, Yann Echelard, a director of TG Therapeutics, acquired 22,250 shares of common stock.
• The acquisition was a grant of restricted shares.
• These restricted shares will vest on June 14, 2025.
• Following the transaction, Echelard beneficially owns 244,098 shares of TG Therapeutics, which includes restricted common stock vesting over various time periods.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock grant to a director. While insider ownership is generally positive, this is part of a compensation package.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The increase in insider ownership could be viewed positively by shareholders.

Key Dates